Thalidomide (HAL) maintenance following high-dose melphalan with autologous stem cell transplant (ASCT) for myeloma.

被引：0
|
作者：
Chang, Julie E. [1 ]
Juckett, Mark B. [1 ]
Kahl, Brad. S. [1 ]
Mitchell, Teri L. [1 ]
Gangnon, Ronald E. [1 ]
Callander, Natalie S. [1 ]
Longo, Walter L. [1 ]
机构：
[1] Univ Wisconsin, Dept Hematol & Bone Marrow Transplantat, Madison, WI USA
来源：
BLOOD | 2006年 / 108卷 / 11期
关键词：
D O I：
10.1182/blood.V108.11.5455.5455
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
5455
引用
收藏
页码：459B / 459B
页数：1
相关论文
共 50 条
  • [1] Thalidomide maintenance following high-dose melphalan with autologous stem cell support in myeloma
    Chang, Julie E.
    Juckett, Mark B.
    Callander, Natalie S.
    Kahl, Brad S.
    Gangnon, Ronald E.
    Mitchell, Teri L.
    Longo, Walter L.
    CLINICAL LYMPHOMA & MYELOMA, 2008, 8 (03): : 153 - 158
  • [2] High-dose melphalan and etoposide prior to autologous hematopoietic stem cell transplant is an effective regimen in the treatment of multiple myeloma.
    Briggs, AD
    Taylor, CW
    Sturm, TJ
    Shapiro, TW
    List, AF
    BLOOD, 1998, 92 (10) : 362B - 362B
  • [3] Pegfilgrastim versus filgrastim to accelerate hematopoietic recovery after high dose melphalan and autologous hematopoietic stem cell transplant (ASCT) for multiple myeloma.
    Olin, RL
    Luger, SM
    Porter, DL
    Schuster, SJ
    Tsai, D
    Nasta, S
    Perl, A
    Loren, AW
    Goldstein, S
    Mangan, P
    Sherry, V
    Cunningham, K
    Sachs, B
    Hummel, K
    Stadtmauer, EA
    BLOOD, 2004, 104 (11) : 382B - 383B
  • [4] A Phase I Trial of Zevalin Radioimmunotherapy with High-Dose Melphalan (HDM) and Autologous Stem Cell Transplant (ASCT) for Multiple Myeloma (MM)
    Dispenzieri, Angela
    Gertz, Morie Abraham
    Lacy, Martha Q.
    Laumann, Kristina
    LaPlant, Betsy R.
    Kumar, Shaji
    Buadi, Francis K.
    Hayman, Suzanne R.
    Dingli, David
    Hogan, William J.
    Ansell, Stephen M.
    Gastineau, Dennis A.
    Inwards, David James
    Micallef, Ivana N.
    Porrata, Luis F.
    Johnston, Patrick B.
    Litzow, Mark R.
    Witzig, Thomas E.
    BLOOD, 2011, 118 (21) : 1337 - 1338
  • [5] High-dose lenalidomide and melphalan as conditioning for autologous stem cell transplantation in relapsed or refractory multiple myeloma.
    Rossi, Adriana C.
    Monge, Jorge
    Niesvizky, Ruben
    Hsu, Jing Mei
    Shore, Tsiporah
    Van Besien, Koen
    Pearse, Roger
    Mark, Tomer
    Jayabalan, David
    Mayer, Sebastian Alexander
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [6] ASCT and high-dose melphalan in multiple myeloma
    Sharma, Sharan Prakash
    LANCET ONCOLOGY, 2014, 15 (11): : E481 - E481
  • [7] Thalidomide maintenance after autologous stem cell transplantation for multiple myeloma.
    Grosskreutz, CL
    Egan, R
    Scigliano, E
    Fruchtman, SM
    Isola, LM
    BLOOD, 2003, 102 (11) : 489B - 490B
  • [8] High-Dose Gemcitabine Combined With Busulfan and Melphalan (Gem/Bu/Mel) With Autologous Stem-Cell Transplant (ASCT) In Refractory and Relapsed Myeloma
    Nieto, Yago
    Shah, Nina
    Popat, Uday R.
    Jones, Roy B.
    Bashir, Qaiser
    Bassett, Rolland
    Valdez, Benigno C.
    Andersson, Bone S.
    Parmar, Simrit
    Orlowski, Robert Z.
    Shah, Jatin J.
    Thomas, Sheeba K.
    Wang, Michael
    Champlin, Richard E.
    Qazilbash, Muzaffar
    BLOOD, 2013, 122 (21)
  • [9] High-dose chemotherapy with autologous stem cell rescue in multiple myeloma.
    Mahendra, P
    Ethell, M
    Johnson, D
    Seale, J
    Bass, G
    Marcus, RE
    BRITISH JOURNAL OF HAEMATOLOGY, 1996, 93 : 297 - 297
  • [10] Arsenic trioxide with ascorbic acid and high-dose melphalan for autologous hematopoietic stem cell transplantation for multiple myeloma.
    Qazilbash, Muzaffar H.
    Saliba, Rima M.
    Davis, Marilyn S.
    Mendoza, Floralyn L.
    Hosing, Chitra
    Couriel, Daniel R.
    De Lima, Marcos
    Kebriaei, Partow
    Weber, Donna M.
    Wang, Michael
    Alousi, Arnin M.
    Matthes, Steven G.
    Jones, Roy B.
    Champlin, Richard E.
    Giralt, Sergio A.
    BLOOD, 2006, 108 (11) : 881A - 881A
12345